Aradigm Corporation (NASDAQ:ARDM) Files An 8-K Other Events

ME Staff 8-k
-
0

Aradigm Corporation (NASDAQ:ARDM) Files An 8-K Other Events
Item 8.01 Other Events

On October 30, 2019, Aradigm Corporation (the “Company”) announced via a press release that the Company has withdrawn its European Marketing Authorization Application (MAA) for Linhaliq as a treatment for non-cystic fibrosis bronchiectasis. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1    Press Release of Aradigm Corporation dated October 30, 2019


ARADIGM CORP Exhibit
EX-99.1 2 d827492dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 October 30,…
To view the full exhibit click here

About Aradigm Corporation (NASDAQ:ARDM)

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.